
Olaparib





SCORE
CURATIVE
Overall Survival / Disease-Free Survival / Pathological Complete Response
NON-CURATIVE
Overall Survival
Progression-Free Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response
Overall Survival / Disease-Free Survival / Pathological Complete Response
NFORMATION
Tumour type: Gynaecological Malignancies

Therapeutic Indication: Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability Experimental Arm: Olaparib + Bevacizumab Control Arm: Placebo + bevacizumab

